Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Nat Med. 2015 May 11;21(6):601–609. doi: 10.1038/nm.3843

Figure 2.

Figure 2

Dynamin oligomerization ameliorates transient proteinuria. (a) Plasma pharmacokinetics of Bis-T-23 after injection (40 mg/kg) in C57BL/6J mice (n = 3) as measured by mass spectrometry. (b) Proteinuria of C57BL/6J mice determined by spot urine test before injection (0 h) and at the indicated hours after injection of the indicated concentrations of Bis-T-23. NS, not statistically significant (unpaired t-test; n = 5 mice per concentration). (c-e) Inulin clearance (c), urine volume (d) and para-aminohippurate (PAH) clearance (e) of C57BL/6J mice determined after 8 consecutive days of treatment with DMSO (1%, vehicle) or Bis-T-23 (40 mg/kg). Error bars, mean ± SD (n = 6 mice per condition). (f) The systolic (SYS) or diastolic (DIA) blood pressure of 129X1/SvJ mice measured invasively using a carotid catheter after 8 consecutive days of treatment with DMSO (1%, vehicle) or Bis-T-23 (40 mg/kg) (n = 3 mice per condition). (g) Proteinuria of BALB/c mice determined by spot urine test at indicated times after two consecutive doses of LPS. As indicated, animals were injected with either DMSO (1%, vehicle) or Bis-T-23 (40 mg/kg) (n = 10 mice per condition). Error bars, mean ± SD (*P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, unpaired t-test). (h) Proteinuria of Sprague-Dawley rats treated with PAN and determined by spot urine test. Rats were treated once a day starting 12 days after PAN with DMSO (1%, vehicle) or Bis-T-23 (20 mg/kg) for 6 consecutive days (n = 6 rats per condition). Error bars, mean ± SD (*P ≤ 0.05; ***P ≤ 0.001, unpaired t-test).